Skip to main content
Equibles
DRIO logo

DRIO · DarioHealth Corp. · Metrics

Track DRIO — free

Use DRIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DRIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.38 -0.35 (-12.84%) At close · Nov 6 Q1 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — cleared Aug 11, 2026

The latest filing no longer states the doubt (first flagged May 13, 2026).

View the 10-Q filed Aug 11, 2026
Market Cap
$23.27M
Shares
9.80M
Volume · Nov 6 14.9K Avg daily vol (3M) 38.18K

DRIO metrics

78 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.38
Market cap
$23.27M

Price action

23 metrics
Price change (1W)
-17.7%
Price change (30D)
-55.2%
Price change (3M)
-64.8%
Price change (6M)
-66.5%
Price change (YTD)
-76.1%
Price change (1Y)
-79.9%
Trailing year
Price change (5Y)
—
52-week high
$14.00
52-week low
$2.73
Change from 52-week high
-80.5%
Change from 52-week low
+0.0%
Annualized volatility
83.0%
Annualized volatility (3M)
75.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.5
RSI (14D)
21.5
Price vs SMA 50
-51.6%
Price vs SMA 200
-64.0%
Avg volume (3M)
38,010
Relative volume
1.9
Average dollar volume
$192,189

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
9.80M

Valuation

12 metrics
P / E (TTM)
0.5
Trailing earnings · reciprocal yield 213.2%
PEG ratio
—
EV / revenue
2.1×
reciprocal yield 47.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 78.6%
P / book
0.5
reciprocal yield 206.3%
FCF yield
-95.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-133.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.1×
reciprocal yield 47.6%
EV / revenue historical average (5Y)
3.3×
reciprocal yield 30.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-31

Profitability

9 metrics
Gross margin
58.2%
Operating margin
-151.6%
Trailing 12 months
Net margin
-169.9%
Gross profit (TTM)
$12.21M
Operating profit (TTM)
−$31.83M
Net income (TTM)
−$35.67M
Trailing 12 months
Diluted EPS (TTM)
$5.81
FCF margin
-121.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$9.84

Growth

11 metrics
Revenue growth YoY
-3.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$21.00M
Trailing 12 months
EPS growth YoY
-76.0%
Shares change YoY
+276.5%
Year over year · more shares
Revenue CAGR (3Y)
-6.8%
Revenue CAGR (5Y)
+24.2%
EPS CAGR (3Y)
-41.6%
EPS CAGR (5Y)
-33.9%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-64.8%
Return on assets
-36.9%
Debt / equity
0.6
Current ratio
2.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$25.48M
Quick ratio
1.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$17.10M
Latest balance sheet
Cash & equivalents
$6.63M
Total assets
$96.59M
Total debt
$31.06M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$25.34M
Capital expenditures (TTM)
$136,000
R&D (TTM)
$10.45M
SG&A (TTM)
—
Stock compensation (TTM)
$1.22M
R&D / revenue
49.7%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
21
13F filer change QoQ
0
Institutional ownership
8.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
8.7%
Private-fund adviser ownership
8.7%
Active holders' share change QoQ
-1.5%
Holder tenure
21.1
Price vs estimated holder cost
-34.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
0.8%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
32 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1533998 CUSIP 23725P308 13F (30d) 12 filings 6 filers Visit website Investor relations